Evidence map›Paper›PMID 40056197›Full record

ArticleVirchows Archiv : an international journal of pathology2025

Implementing digital pathology: qualitative and financial insights from eight leading European laboratories.

Xavier Matias-Guiu, Jordi Temprana-Salvador, Pablo Garcia Lopez, Solene-Florence Kammerer-Jacquet, Nathalie Rioux-Leclercq, David Clark, Christian M Schürch, Falko Fend, Sven Mattern, David Snead and 14 more

Abstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Xavier Matias-GuiuHospital Universitari de Bellvitge and Hospital Universitari Arnau de Vilanova IDIBELL, IRBLLEIDA, University of Lleida, CIBERONC, Lleida, Spain. fjmatiasguiu.lleida.ics@gencat.cat.ORCID http://orcid.org/0000-0002-7201-6605
Jordi Temprana-SalvadorPathology Department, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9516-1680
Pablo Garcia LopezInstitut Català de La Salut (ICS), Barcelona, Spain.
Solene-Florence Kammerer-JacquetCytology and Pathological Anatomy Department, Rennes University Hospital, Rennes, France.ORCID http://orcid.org/0000-0002-6623-741X
Nathalie Rioux-LeclercqCytology and Pathological Anatomy Department, Rennes University Hospital, Rennes, France.ORCID http://orcid.org/0000-0002-3042-7510
David ClarkNottingham University Hospitals NHS Trust, HMDN, Dept of Histopathology, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK.ORCID http://orcid.org/0000-0002-1575-8119
Christian M SchürchDepartment of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-1792-1768
Falko FendDepartment of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-5496-293X
Sven MatternInstitute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany.
David SneadUHCW NHS Trust, Coventry, CV2 2DX, UK.ORCID http://orcid.org/0000-0002-0766-9650
Nicola FuscoEuropean Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0002-9101-9131
Elena Guerini-RoccoEuropean Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0003-2001-7582
Federico RojoIIS-Fundación Jiménez Díaz-CIBERONC, Madrid, Spain.ORCID http://orcid.org/0000-0001-9989-0290
Marie BrevetTechnipath, Dommartin, France & Biwako, Lyon, France.ORCID http://orcid.org/0000-0003-2275-691X
Manuel Salto TellezPrecision Medicine Centre, Queen'S University Belfast, Belfast, UK.ORCID http://orcid.org/0000-0001-8586-282X
Angelo Dei TosDepartment of Integrated Diagnostics, University of Padua, Padua, Italy.
Thomas di MaioRegional Diagnostics AstraZeneca, 6340, Basel, Zug/CH, Switzerland.
Silvia Ramírez-PeinadoOncology Digital-Precision Healthcare, AstraZeneca, 08028, Barcelona, ES, Spain.
Elizabeth SheppardOncology Market Access & Pricing, AstraZeneca, Cambridge, UK.
Huw BannisterOncology Diagnostics, AstraZeneca, Cambridge, UK.
Anastasios GkiokasAlira Health, Basel, Switzerland.
Mario ArpaiaAlira Health, Barcelona, Spain.
Ons Ben DhiaAlira Health, Paris, France.
Nazario MartinoAlira Health, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digital Pathology (DP) revolutionizes the diagnostic workflow. Digitized scanned slides enhance operational efficiency by facilitating remote access, slide storage, reporting and automated AI image analysis, and enabling collaboration and research. However, substantial upfront and maintenance costs remain significant barriers to adoption. This study evaluates DP's financial and qualitative value, exploring whether the long-term financial benefits justify investments and addressing implementation challenges in large public and private European laboratory settings. A targeted literature review, semi-structured interviews, surveys, and a net present value (NPV) model were employed to assess DP's impact on clinical practice and laboratory financials. Qualitative findings validate the key benefits of DP, including optimized workflow, enhanced logistics, and improved laboratory organization. Pathologists reported a smooth integration, improved training, teaching, and research capabilities, and increased flexibility through remote work. Collaboration within multidisciplinary teams was strengthened, while case examination efficiency and access to archival slides were notably improved. Quantitative results indicate that DP demonstrates strong financial potential, achieving cost recovery within 6 years. DP investment results in a 7-year NPV of + €0.21 million (m) driven by increased productivity and diagnosis volumes. Although the high upfront costs for scanners, training, and system integration pose a significant barrier to the adoption of DP, larger institutions are better positioned to leverage economies of scale. This study underscores the importance of sustained financial support to cope with the initial investment and regional collaboration in driving widespread adoption of DP. Expanding reimbursement policies for pathology procedures could significantly reduce financial barriers.

Indexed as

Laboratories, ClinicalPathology, ClinicalTelepathologyEuropeHumansWorkflowDigital pathologyEconomic outcomesPathologist perceptionWorkflow impact

Identifiers

PMID40056197
PMCPMC12546502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.